Effect on lipid profiles of switching from olanzapine to another secondgeneration antipsychotic agent in veterans with schizophrenia

Garman, Patrick M.; Ried, L. Douglas; Bengtson, Michael A.; Hsu, Chienning; McConkey, Joel R.

doi:10.1331/japha.2007.06090

Cited by 22 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Switching to quetiapine was found to correct serum lipid profiles (Garman et al, 2007) and help to increase sexual functionality (Kaneda and Ohmori, 2003;Kaneda et al, 2004;Nakajima et al, 2005). We refrain from making assumptions about lipid profiles and sexual functions of our patients because of lack of data; however, one of the most common reasons for switching to quetiapine in our patients was weight gain.…”

Section: Discussionmentioning

confidence: 84%

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Alptekın¹,

Aydin

Gucer

et al. 2010

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The aim of the study was to evaluate the adherence and efficacy of quetiapine treatment in a 6-month, multicentre, noninterventional naturalistic design. Overall, 710 schizophrenia patients using quetiapine or who had switched to quetiapine were included. The continuation rate for quetiapine treatment during 6-month follow-up period was 69%. Adherence improved with each subsequent visit for continued patients, 92.9% at the second visit to 96.1% at the last. Treatment adherence was correlated to improvement of symptoms, though not significantly. Patients having lower clinical global impression severity scores at the beginning were twice as likely to improve compared with patients with higher clinical global impression scores. Schizophrenia patients with antisocial behaviour problems had two and a half times higher drop-out rates. In conclusion, this naturalistic study showed that adherence to quetiapine treatment was high, and treatment was effective in schizophrenia patients during long-term treatment. Remission of symptoms in schizophrenia is much related to severity of symptoms at baseline, treatment adherence and characteristics of patients such as antisocial behavioural patterns.

show abstract

Section: Discussionmentioning

confidence: 84%

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Alptekın¹,

Aydin

Gucer

et al. 2010

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Often comparable, or improved efficacy and tolerability were the result. Varied improvements in metabolics and even cognition have been noted throughout (Garman et al, 2003;Weiden et al, 2003Weiden et al, , 2006Weiden et al, , 2008Harvey et al, 2004;Bartko et al, 2006;Montes et al, 2007;Lublin et al, 2009;Rossi et al, 2008).…”

Section: Switching To Ziprasidonementioning

confidence: 99%

Ziprasidone in the Treatment of Bipolar Disorder

Schwartz

Stahl

Pappadopulos

et al. 2011

Bipolar Psychopharmacotherapy

View full text Add to dashboard Cite

“…[196][197][198][199] Adverse metabolic effects that cannot be managed conservatively may require pharmacological interventions for obesity, hyperlipidaemia or diabetes. [200][201][202] In addition, specific psychotropic and other treatments for drug-induced weight gain, hyperglycaemia or hyperlipidaemia includes consideration of: (i) selective monoamine transport inhibitors (bupropion, sibutramine, psychostimulants);…”

Section: Clinical Management Of Metabolic Syndromementioning

confidence: 99%

“…[238] Dyslipidaemia can be limited by using antipsychotics with relatively low risk of adverse metabolic effects, including aripiprazole and ziprasidone. [197,[239][240][241] Aripiprazole, and possibly quetiapine or risperidone, may be of benefit in increased bodyweight and dyslipidaemia, as well as new-onset type 2 diabetes, but clinical testing and comparison of such options remain inadequate. [197,[239][240][241] Statins can reduce serum levels of triglycerides as well as cholesterol following increases in association with treatment with various antipsychotic drugs.…”

Section: Clinical Management Of Metabolic Syndromementioning

confidence: 99%

“…[197,[239][240][241] Aripiprazole, and possibly quetiapine or risperidone, may be of benefit in increased bodyweight and dyslipidaemia, as well as new-onset type 2 diabetes, but clinical testing and comparison of such options remain inadequate. [197,[239][240][241] Statins can reduce serum levels of triglycerides as well as cholesterol following increases in association with treatment with various antipsychotic drugs. [242] In general, prevention of obesity (BMI ‡30 kg/m 2 ) and the metabolic syndrome among psychiatric patients includes repeated encouragement of lifestyle changes, including increased regular exercise, dietary modifications and smoking cessation -all supported and enhanced by collaborations with primary care physicians and other health professionals to increase access to interventions and programmes aimed at improving general health.…”

Section: Clinical Management Of Metabolic Syndromementioning

confidence: 99%

See 1 more Smart Citation

Adverse Endocrine and Metabolic Effects of Psychotropic Drugs

et al. 2009

View full text Add to dashboard Cite

The article critically reviews selected, clinically significant, adverse endocrine and metabolic effects associated with psychotropic drug treatments, including hyperprolactinaemia, hyponatraemia, diabetes insipidus, hypothyroidism, hyperparathyroidism, sexual dysfunction and virilization, weight loss, weight gain and metabolic syndrome (type 2 diabetes mellitus, dyslipidaemia and hypertension). Such effects are prevalent and complex, but can be managed clinically when recognized. They encourage continued critical assessment of benefits versus risks of psychotropic drugs and underscore the importance of close coordination of psychiatric and general medical care to improve long-term health of psychiatric patients. Options for management of hyperprolactinaemia include lowering doses, switching to agents such as aripiprazole, clozapine or quetiapine, managing associated osteoporosis, carefully considering the use of dopamine receptor agonists and ruling out stress, oral contraceptive use and hypothyroidism as contributing factors. Disorders of water homeostasis may include syndrome of inappropriate antidiuretic hormone (SIADH), managed by water restriction or slow replacement by hypertonic saline along with drug discontinuation. Safe management of diabetes insipidus, commonly associated with lithium, involves switching mood stabilizer and consideration of potassium-sparing diuretics. Clinical hypothyroidism may be a more useful marker than absolute cut-offs of hormone values, and may be associated with quetiapine, antidepressant and lithium use, and managed by thyroxine replacement. Hyper-parathyroidism requires comprehensive medical evaluation for occult tumours. Hypocalcaemia, along with multiple other psychiatric and medical causes, may result in decreased bone density and require evaluation and management. Strategies for reducing sexual dysfunction with psychotropics remain largely unsatisfactory. Finally, management strategies for obesity and metabolic syndrome are reviewed in light of the recent expert guidelines, including risk assessment and treatments, such as monoamine transport inhibitors, anticonvulsants and cannabinoid receptor antagonists, as well as lifestyle changes.

show abstract

Effect on lipid profiles of switching from olanzapine to another secondgeneration antipsychotic agent in veterans with schizophrenia

Cited by 22 publications

References 15 publications

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Ziprasidone in the Treatment of Bipolar Disorder

Adverse Endocrine and Metabolic Effects of Psychotropic Drugs

Contact Info

Product

Resources

About